Q3: 2025-11-06 Earnings Abstract
EPS of -$0.19 misses by $0.03
| Income of $8.96M (37.62% Y/Y) beats by $2.62M
AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Name November 6, 2025 5:00 PM EST
Firm Individuals
Tryn Stimart – Chief Authorized Officer, CCO, Compliance Officer, Company Secretary & Privateness Officer
Carl L. Hansen – CEO, President & Chairperson
Andrew Sales space – Chief Monetary Officer
Convention Name Individuals
Malcolm Hoffman – BMO Capital Markets Fairness Analysis
Andrea Tan – Goldman Sachs Group, Inc., Analysis Division
Joshua Nickerson – Stifel, Nicolaus & Firm, Included, Analysis Division
Faisal Khurshid – Leerink Companions LLC, Analysis Division
Steven Dechert – KeyBanc Capital Markets Inc., Analysis Division
Jacqueline Kisa – TD Cowen, Analysis Division
Presentation
Operator
Good afternoon, and welcome to AbCellera’s Third Quarter 2025 Enterprise Replace Convention Name. My identify is Cameron, and I am going to facilitate the audio portion of right now’s interactive broadcast. [Operator Instructions] Right now, I want to flip the decision over to Tryn Stimart, AbCellera’s Chief Authorized and Compliance Officer. Chances are you’ll proceed.
Tryn Stimart
Chief Authorized Officer, CCO, Compliance Officer, Company Secretary & Privateness Officer
Thanks. Hey, everybody. Thanks for becoming a member of us for AbCellera’s Third Quarter 2025 Earnings Name. I am Tryn Stimart, AbCellera’s Chief Authorized and Compliance Officer. Dr. Carl Hansen, AbCellera’s President and CEO; and Andrew Sales space, AbCellera’s Chief Monetary Officer, are additionally on right now’s name. Throughout this name, we anticipate making projections and forward-looking statements primarily based on our present expectations and in accordance with the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995. Our precise outcomes might differ materially because of a number of components outlined in our newest Type 10-Okay and subsequent Varieties 10-Q and 8-Q (sic) [ 8-K ] filed with the Securities and Alternate Fee.
AbCellera just isn’t obligated to replace any forward-looking statements, whether or not because of new info, future occasions or in any other case. Our presentation right now, our earnings press launch and our SEC filings can be found on our Investor Relations